Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA pins protein vaccination

被引:281
作者
Letvin, NL
Montefiori, DC
Yasutomi, Y
Perry, HC
Davies, ME
Lekutis, C
Alroy, M
Freed, DC
Lord, CI
Handt, LK
Liu, MA
Shiver, JW
机构
[1] DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710
[2] HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,BOSTON,MA 02215
[3] MERCK RES LABS,DEPT VIRUS & CELL BIOL,W POINT,PA 19486
关键词
CTL; virus neutralization; vaccine; SHIV; T lymphocyte;
D O I
10.1073/pnas.94.17.9378
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
It is generally thought that an effective vaccine to prevent HIV-1 infection should elicit both strong neutralizing antibody and cytotoxic T lymphocyte responses, We recently demonstrated that potent, boostable, long-lived HIV-1 envelope (Env)-specific cytotoxic T lymphocyte responses can be elicited in rhesus monkeys using plasmid-encoded HIV-1 env DNA as the immunogen, In the present study, we show that the addition of HIV-I Env protein to this regimen as a boosting immunogen generates a high titer neutralizing antibody response in this nonhuman primate species, Moreover, we demonstrate in a pilot study that immunization with HIV-1 env DNA (multiple doses) followed by a final immunization with HIV-1 env DNA plus HIV-1 Env protein (env gene from HXBc2 clone of HIV IIIB; Env protein from parental HIV IIIB) completely protects monkeys from infection after i.v. challenge with a chimeric virus expressing HIV-1 env (HXBc2) on a simian immunodeficiency virus(mac) backbone (SHIV-HXBc2). The potent immunity and protection seen in these pilot experiments suggest that a DNA prime/DNA plus protein boost regimen warrants active investigation as a vaccine strategy to prevent HIV-1 infection.
引用
收藏
页码:9378 / 9383
页数:6
相关论文
共 25 条
[1]   Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1 [J].
Berman, PW ;
Murthy, KK ;
Wrin, T ;
Vennari, JC ;
Cobb, EK ;
Eastman, DJ ;
Champe, M ;
Nakamura, GR ;
Davison, D ;
Powell, MF ;
Bussiere, J ;
Francis, DP ;
Matthews, T ;
Gregory, TJ ;
Obijeski, JF .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :52-59
[2]  
BORROW P, 1994, J VIROL, V68, P5103
[3]   PROTECTIVE EFFECTS OF A LIVE ATTENUATED SIV VACCINE WITH A DELETION IN THE NEF GENE [J].
DANIEL, MD ;
KIRCHHOFF, F ;
CZAJAK, SC ;
SEHGAL, PK ;
DESROSIERS, RC .
SCIENCE, 1992, 258 (5090) :1938-1941
[4]   PRECLINICAL EFFICACY OF A PROTOTYPE DNA VACCINE - ENHANCED PROTECTION AGAINST ANTIGENIC DRIFT IN INFLUENZA-VIRUS [J].
DONNELLY, JJ ;
FRIEDMAN, A ;
MARTINEZ, D ;
MONTGOMERY, DL ;
SHIVER, JW ;
MOTZEL, SL ;
ULMER, JB ;
LIU, MA .
NATURE MEDICINE, 1995, 1 (06) :583-587
[5]   RESISTANCE OF CHIMPANZEES IMMUNIZED WITH RECOMBINANT GP120(SF2) TO CHALLENGE BY HIV-1(SF2) [J].
ELAMAD, Z ;
MURTHY, KK ;
HIGGINS, K ;
COBB, EK ;
HAIGWOOD, NL ;
LEVY, JA ;
STEIMER, KS .
AIDS, 1995, 9 (12) :1313-1322
[6]   DNA VACCINES - PROTECTIVE IMMUNIZATIONS BY PARENTERAL, MUCOSAL, AND GENE-GUN INOCULATIONS [J].
FYNAN, EF ;
WEBSTER, RG ;
FULLER, DH ;
HAYNES, JR ;
SANTORO, JC ;
ROBINSON, HL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (24) :11478-11482
[7]   PROGRESS IN AIDS VACCINE DEVELOPMENT [J].
JOHNSTON, MI .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1995, 108 (04) :313-317
[8]   KINETICS OF GAG-SPECIFIC CYTOTOXIC T-LYMPHOCYTE RESPONSES DURING THE CLINICAL COURSE OF HIV-1 INFECTION - A LONGITUDINAL ANALYSIS OF RAPID PROGRESSORS AND LONG-TERM ASYMPTOMATICS [J].
KLEIN, MR ;
VANBAALEN, CA ;
HOLWERDA, AM ;
KERKHOFGARDE, SR ;
BENDE, RJ ;
KEET, IPM ;
EEFTINCKSCHATTENKERK, JKM ;
OSTERHAUS, ADME ;
SCHUITEMAKER, H ;
MIEDEMA, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (04) :1365-1372
[9]   TEMPORAL ASSOCIATION OF CELLULAR IMMUNE-RESPONSES WITH THE INITIAL CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SYNDROME [J].
KOUP, RA ;
SAFRIT, JT ;
CAO, YZ ;
ANDREWS, CA ;
MCLEOD, G ;
BORKOWSKY, W ;
FARTHING, C ;
HO, DD .
JOURNAL OF VIROLOGY, 1994, 68 (07) :4650-4655
[10]  
Lekutis C, 1997, J IMMUNOL, V158, P4471